Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Smith & Nephew plc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.62 (market cap $157.51B), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 12.6× Smith & Nephew plc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| BBVA | SNN | |
|---|---|---|
Market Cap | $157.51B | $12.50B |
Sector | Financials | Health |
52-Week High | $28.36 | $38.70 |
52-Week Low | $17.96 | $28.73 |
Dividend Yield | 3.8% | 2.64% |
Enterprise Value | — | $15.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.35, up 0.75% today, with a bullish technical signal from moving averages and strong fundamental performance. The bank reported Q2 2026 net profit growth of 11.4% year-over-year, driven by Mexico operations, and announced a $2.3 billion buyback. Revenue reached $39.42 billion in 2025, with net income margin at 26.13% and ROE of 18.5%, though cash flow was negative in 2024.
Outlook is positive with raised profitability guidance (ROTE ~21%) and analyst consensus leaning buy (54%), but risks include a Spanish court trial for spying allegations and antitrust probes. The stock offers value with a P/E of 12.98, yet investors should monitor legal overhangs and macroeconomic volatility in core markets like Spain and Mexico.
SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.
The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
